Aardvark COO exits to lead new dermatology subsidiary; CFO Sun adds COO role

Aardvark Therapeutics, Inc.

Bryan Jones stepped down as COO of Aardvark on Feb 9, 2026, to become CEO of wholly-owned subsidiary Ardia Therapeutics.
Ardia will develop DIA-615, a topical treatment for inflammatory skin diseases including psoriasis.
CFO Nelson Sun appointed COO in addition to his CFO role, effective Feb 9, 2026; no compensation change.
Derrick C. Li appointed Chief Business Officer, effective Feb 9, 2026.
Jones received accelerated vesting of 17,797 shares and continued option exercise while at Ardia; waived severance.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.